Combination therapy effective for patients with higher-risk myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML)

Combination therapy effective for patients with higher-risk myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML)
Combination therapy effective for patients with higher-risk myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML)

A phase II study that investigated the potential of the drugs azacitidine and lenalidomide, demonstrated that the two therapies in combination may be an effective frontline treatment regimen for patients with higher-risk forms of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).

These results were presented at the 56th annual meeting of the American Society of Hematology in San Francisco, California.

Myelodysplastic syndrome is a type of cancer in which the bone marrow does not make enough healthy blood cells, resulting in abnormal (blast) cells in the blood and/or bone marrow. Patients with higher-risk disease experience an unusually large percentage of blasts in their blood. Patients often develop infections, anemia, or excessive bleeding. Acute myeloid leukemia (AML) is a blood cell cancer and is the most common acute leukemia affecting adults, incidence of which increases with age.

The study, led by Guillermo Garcia-Manero, MD, professor of leukemia at The University of Texas MD Anderson Cancer Center in Houston, shed new light on effective dosage schedule and amounts for the drugs, something previously unknown. The combination therapy was well tolerated in the study of 88 patients.

"Hypomethylating (HMA) agents such as azacitidine and lenalidomide are currently the front line of therapeutic choice for patients with higher-risk MDS, and also frequently employed in elderly patients with AML not otherwise eligible for standard intensive therapy," said presenter Courtney DiNardo, MD, of MD Anderson.

"A number of combination strategies are under development to improve the results of HMA therapy. Given what we know about the effectiveness of azacitidine and lenalidomide in patients with MDS and AML, a scientific rationale existed to explore this therapeutic combination strategy."

DiNardo's team evaluated the administration of azacitidine and lenalidomide on days 6 to 10 of a 28-day cycle of treatment. The combination therapy appeared to be effective in patients presenting with as high as 30% blast cells.

"The responses were rapid with a median of two cycles for the drugs to be effective. Treatment with this dosage and schedule was well tolerated," said DiNardo.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs